ELX-02 clinical trials
Also written ELX-02.
How each study uses ELX-02 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ELX-02 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2019 (4)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 4 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Eloxx Pharmaceuticals, Inc. (9)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test ELX-02.
- Jun 2027EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and SafetyPhase 2 · Eloxx Pharmaceuticals, Inc.
Studies
Open first, then newest update. How each study uses ELX-02 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and SafetyRecruitingPhase 2Eloxx Pharmaceuticals, Inc.NCT07523581Written as Exaluren
- A Study of ELX-02 in Patients With Alport SyndromeCompletedPhase 2Eloxx Pharmaceuticals, Inc.NCT05448755Written as ELX-02
- Phase 1 Study of ELX-02 in Healthy AdultsCompletedPhase 1Eloxx Pharmaceuticals, Inc.NCT03292302Written as ELX-02
- A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X AlleleCompletedPhase 2Eloxx Pharmaceuticals, Inc.NCT04126473Written as ELX-02
- A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X AlleleCompletedPhase 2Eloxx Pharmaceuticals, Inc.NCT04135495Written as ELX-02
- A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02CompletedPhase 1Eloxx Pharmaceuticals, Inc.NCT03776539Written as ELX-02
- Phase 1 Study of ELX-02 in Healthy Adult SubjectsCompletedPhase 1Eloxx Pharmaceuticals, Inc.NCT03309605Written as ELX-02
- A Phase 2 Study of ELX-02 in Patients With Nephropathic CystinosisTerminatedPhase 2Eloxx Pharmaceuticals, Inc.NCT04069260Written as ELX-02
- Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult VolunteersTerminatedPhase 1Eloxx Pharmaceuticals, Inc.NCT02807961Written as ELX-02